Gene therapy is becoming a promising solution for retinal degenerative diseases, as the retina offers an excellent setting for studying and treating eye conditions. Importantly, it was the first ti...
Smoldering Multiple Myeloma (SMM) is an asymptomatic condition that acts as an intermediate stage between monoclonal gammopathy of undetermined significance (MGUS) and multiple myeloma. First described by Kyle and Greipp in 1980, SMM typically affects individuals aged 50 to 70 and is usually diagnosed incidentally ...
Find MoreTakeda and AC Immune Ink Exclusive Deal for Active Immunotherapy in Alzheimer’s, Focusing on Amyloid Beta Takeda and AC Immune SA have unveiled an exclusive global option and licensing pact concerning AC Immune’s active immunotherapies directed at harmful variants of amyloid beta (Abeta), notably ACI-24.060, int...
Find MoreX4 Pharmaceuticals has gained approval for its first product, XOLREMDI (mavorixafor), marking its entrance into the commercial rare disease market. The FDA approved mavorixafor on April 29, 2024, specifically for patients aged 12 and above diagnosed with WHIM syndrome (characterized by warts, hypogammaglobulinemia,...
Find MoreFDA Greenlights XOLREMDI Capsules from X4 Pharmaceuticals for WHIM Syndrome Treatment X4 Pharmaceuticals has declared that the FDA has granted approval for XOLREMDI™ (mavorixafor) capsules to be utilized in individuals aged 12 and above who have WHIM syndrome (characterized by warts, hypogammaglobulinemia, infec...
Find MoreIpsen Partners with Skyhawk Therapeutics for RNA-Focused Research in Rare Neurological Disorders Ipsen and Skyhawk Therapeutics have entered into an exclusive global partnership to explore and create new small molecules that can influence RNA for rare neurological conditions. Under this agreement, Ipsen has the ...
Find MoreRoche's Columvi Achieves Primary Endpoint of Prolonged Overall Survival in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Trial Roche reported that the Phase III STARGLO trial successfully achieved its main goal of improving overall survival. The research revealed that in...
Find MoreAs we step into the crisp corridors of 2024, the healthcare landscape unfolds a compelling saga of mergers, strategic funding, and transformative acquisitions. In this month-by-month analysis, we delve into the intricate tapestry of industry dynamics, exploring the impactful maneuvers that are shaping the healthcar...
Find MoreThe progress of mRNA-based therapeutics involves several key stages, including mRNA design, synthesis, entrapment, pharmacodynamics, pharmacokinetics, in vivo and in vitro safety evaluation, manufacturing, and clinical trials. Among these stages, mRNA design and synthesis play pivotal roles in developing mRNA-based...
Find MoreA month following Novartis’ foray into the paroxysmal nocturnal hemoglobinuria (PNH) treatment domain, AstraZeneca strengthens its position in this field as its latest contender, Voydeya, secures a groundbreaking approval in Japan. Voydeya (danicopan), an innovative oral factor D inhibitor, has received approval fr...
Find MoreThough Covid-19 has a significant impact on the supply chain, input costs, logistics, and raw materi.....
Find MoreThe gene therapy in rare diseases market has drastically changed recently due to scientific advancem.....
Find MoreTransthyretin Amyloidosis (ATTR) is a progressive build-up of abnormal deposits of amyloid protein i.....
Find MoreGastroesophageal Reflux Disease (GERD, also known as chronic acid reflux) is a digestive disorder in.....
Find MoreChronic Pancreatitis is an inflammation of the pancreas that can be a result of calcium stones and c.....
Find MoreXerostomia is a condition characterized by dry mouth, which is a result of a reduced or absent flow .....
Find MoreLive Coverage of ASCO 2024 Visit Now for Real-Time Insights and Analytical, Impactful Updates!